By Topic

Pharmacokinetic models in clinical practice: What model to use for DCE-MRI of the breast?

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

4 Author(s)
Litjens, G.J.S. ; Dept. of Biomed. Eng., Eindhoven Univ. of Technol., Eindhoven, Netherlands ; Heisen, M. ; Buurman, J. ; ter Haar Romeny, B.M.

Pharmacokinetic modeling is increasingly used in DCE-MRI high risk breast cancer screening. Several models are available. The most common models are the standard and extended Tofts, the shutter-speed, and the Brix model. Each model and the meaning of its parameters is explained. It was investigated which models can be used in a clinical setting by simulating a range of sampling rates and noise levels representing different MRI acquisition schemes. In addition, an investigation was performed on the errors introduced in the estimates of the pharmacokinetic parameters when using a physiologically less complex model, i.e. the standard Tofts model, to fit curves generated with more complex models. It was found that the standard Tofts model is the only model that performs within an error margin of 20% on parameter estimates over a range of sampling rates and noise levels. This still holds when small complex physiological effects are present.

Published in:

Biomedical Imaging: From Nano to Macro, 2010 IEEE International Symposium on

Date of Conference:

14-17 April 2010